Will imatinib compromise reproductive capacity?
Alberuni M Zamah1, Michael J Mauro, Brian J Druker
1UCSF Medical Center, Center for Reproductive Health, San Francisco, California, USA. RosenM@obgyn.ucsf.edu
The Oncologist
|September 28, 2011
Summary
Imatinib mesylate may negatively impact ovarian function in women undergoing cancer treatment. Fertility preservation options should be discussed due to potential ovarian response compromise during imatinib therapy.
Area of Science:
- Oncology
- Reproductive Endocrinology
Background:
- Imatinib mesylate is a targeted therapy for Philadelphia-positive leukemias and other cancers.
- Increased use of imatinib necessitates consideration of fertility preservation due to gonadotoxic alternatives upon treatment failure.
Observation:
- A case study investigated the effect of imatinib on a patient's ovarian response.
- The patient exhibited a severely compromised ovarian response during gonadotropin stimulation while on imatinib.
Findings:
- Ovarian response normalized after discontinuation of imatinib therapy.
- This suggests a potential reversible negative impact of imatinib on ovarian function.
Implications:
- Imatinib therapy may affect ovarian reserve and response to fertility treatments.
- Further research is needed to understand imatinib's impact on female fertility and guide reproductive counseling.
More Related Videos
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:30Genomic Imprinting and Inheritance
Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...